Abstract

Background: Vitamin B₆ is thought to be a most versatile coenzyme that participates in more than 100 biochemical reactions. It is involved in amino acid and homocysteine metabolism, glucose and lipid metabolism, neurotransmitter production and DNA/RNA synthesis. Vitamin B₆ can also be a modulator of gene expression.

Nowadays, clinically evident vitamin B₆ deficiency is not a common disorder, at least in the general population. Nevertheless, a subclinical, undiagnosed deficiency may be present in some subjects, particularly in the elderly.

Objective: This review gives a complete overview over the metabolism and interactions of vitamin B₆. Further, we show which complications and deficiency symptoms can occur due to a lack of vitamin B₆ and possibilities for public health and supplemental interventions.

Methods: The database Medline (www.ncbi.nlm.nih.gov) was searched for terms like “vitamin B₆”, “pyridoxal”, “cancer”, “homocysteine”, etc. For a complete understanding, we included studies with early findings from the forties as well as recent results from 2006. These studies were summarised and compared in different chapters.

Results and conclusion: In fact, it has been proposed that suboptimal vitamin B₆ status is associated with certain diseases that particularly afflict the elderly population: impaired cognitive function, Alzheimer’s disease, cardiovascular disease, and different types of cancer. Some of these problems may be related to the elevated homocysteine concentrations associated to vitamin B₆ deficiency, but there is also evidence for other mechanisms independent of homocysteine by which a suboptimal vitamin B₆ status could increase the risk for these chronic diseases.

Key words: Vitamin B₆, Coenzyme. Elderly. Homocysteine. Vitamin B₆ deficiency.

Correspondence: Prof. Dr. Marcela González-Gross
Facultad de CC de la Actividad Física y del Deporte
Universidad Politécnica de Madrid
Martin Fierro, s/n
28040 Madrid
E-mail: marcela.gonzalez.gross@upm.es
Aceptado: 10-XII-2006.

Resumen

Antecedentes: se piensa que la vitamina B₆ es la coenzima más versátil que participa en más de 100 reacciones bioquímicas. Está implicada en el metabolismo de los aminoácidos y de la homocisteína, el metabolismo de la glucosa y los lípidos, en la producción de neurotransmisores y en la síntesis de ADN/ARN. Esta vitamina también puede ser un modulador de la expresión génica.

Hoy en día, la deficiencia clínicamente evidente de vitamina B₆ no es una afección habitual, al menos en la población general. Sin embargo, puede ocurrir una deficiencia subclínica no diagnosticada en algunos individuos, especialmente en los ancianos.

Objetivo: esta revisión aporta una visión de conjunto completa sobre el metabolismo y las interacciones de la vitamina B₆. Además, mostramos qué complicaciones y síntomas por deficiencia pueden ocurrir por la falta de vitamina B₆ y las posibilidades de intervenciones de salud pública y de suplementos.


Resultados y conclusión: de hecho, se ha propuesto que el estado sub-óptimo de vitamina B₆ se asocia con ciertas enfermedades que afligen en especial a la población anciana: función cognitiva alterada, enfermedad de Alzheimer, cardiopatía y distintos tipos de cáncer. Algunos de estos problemas podrían relacionarse con concentraciones elevadas de homocisteína asociadas con una deficiencia de vitamina B₆, pero también existe la evidencia de otros mecanismos independientes de la homocisteína por los que un estado sub-óptimo de vitamina B₆ podría aumentar el riesgo de padecer estas enfermedades crónicas.
Introduction

Vitamin B₆ sufficiency is required for optimal health. This is due to the participation in many different biochemical reactions. Vitamin B₆ and its derivatives are needed, especially in their coenzyme functions, for the main metabolic pathways in the human body. For that reason, it is clear that a vitamin B₆ deficiency, even in mild forms, has effects on the human metabolism. Several diseases and impairments of health are connected to the wide variety of B₆ functions in suboptimal status. This can also be worsened through ageing.

This article gets deep into metabolic functions of vitamin B₆ and gives an overview about associated diseases to vitamin B₆ deficiency with new insights from recently published studies, including prevention and treatment potentials.

Vitamin B₆ – Chemistry, metabolism and bioavailability

Vitamin B₆ comprises a group of three related 3-hydroxy-2-methyl-pyrimidine derivatives. The derivative pyridoxine (PN) is an alcohol, pyridoxal (PL) is an aldehyde and pyridoxamine (PM) contains an amino group. Their respective 5´-phosphate esters: pyridoxine 5´-phosphate (PNP), pyridoxal 5´-phosphate (PLP) and pyridoxamin-5´-phosphate (PMP) are the biological active coenzyme forms (fig. 1). They are water-soluble and can be inter-converted in normal human metabolism¹. PLP is the major form that is used by pyridoxine-dependent enzymes. These enzymes catalyse more than 100 essential biochemical reactions in human metabolism.

B₆ vitamers are similarly absorbed in the upper jejunum and little in ileum, but before absorption, phosphate esters must be hydrolysed by alkaline phosphatase or other intestinal phosphatases. The non-phosphorylated form enters the mucosal cells by two different processes according to luminal concentration. At low concentrations, vitamers enter the cell by an active process regulated by requirements. At high concentrations, transport is by non-saturable passive diffusion mechanisms¹. Once in the cell, vitamers are phosphorylated by ATP dependent pyridoxine kinase in a process referred to as metabolic trapping. The phosphorylated form can not traverse cell membranes and must therefore be dephosphorylated again before traversing the basolateral membrane side of the mucosal cell. Once in the circulation, most of B₆ vitamers are transported to the liver where they are again phosphorylated to PNP, PLP or PMP, and then released to plasma². Vitamin B₆ in plasma is mainly PLP (60%), PN (15%) and PL (14%). These vitamers circulate bound to albumin. In peripheral tissues, in order to cross cell membranes, the phosphorylated
functions need to be dephosphorylated by alkaline phosphohosphorylase. Transport into tissue cells is by gradient diffusion. This gradient is maintained thanks to the immediate rephosphorylation occurring inside the cells. Intracellular accumulation of PLP seems to be limited by intracellular protein binding capacity. In circulation, PLP may enter red blood cells where PLP bounds to haemoglobin. In red cell mass, PLP is at higher concentration (4 to 5 times) than in plasma. PLP increases the oxygen affinity of haemoglobin. Total body stores of B6 have been estimated to be as little as 167 mg. Up to 80% of that amount is found in muscle tissue. PLP in metabolism occurs mainly in the liver where it is oxidized to 4-pyridoxic-acid (4-PA) which is released and excreted. Almost 50% of urinary vitamin B6 is 4-PA. In total, some 2 mg vitamin B6 can be excreted every day. In cases of B6 deficiency, excretion appears to be lower. PN is also excreted in faeces but to a limited extent and can therefore be neglected.

Gregory has reviewed the bioavailability of vitamin B6. In a diet typically containing about 15% PN glucoside, which is about 50% as bioavailable as the other vitamins, vitamin B6 is about 75% bioavailable. The bioavailability of non-glucosides of the vitamin is greater than 75%. In the absence of food B6 compounds are absorbed similarly, even at high doses. A loading dose of 50 mg PL or PLP is found up to 70% in the urine within 24 hours. This demonstrates that the phosphate esters are effectively hydrolysed and absorbed in the gut; whereas only 40% PN can be accounted for in the urine under the same conditions, it does raise the plasma PLP concentration and is retained more effectively than PL. Dietary PN and PL are about 10% less effective than PN in raising the plasma PLP concentration, and slightly more of these vitamins are excreted in the urine as 4-PA. Most controlled B6 studies have used PN as the added source, but requirements calculated from these studies would underestimate the B6 requirement by 5% or less for individuals deriving most of their B6 as PLP and PMP from animal source.

Functions and vitamin B6-dependent enzymes

Since vitamin B6 is a coenzyme in many different metabolic reactions, we can consider that vitamin B6 has a wide variety of functions in the human body. PLP, as coenzyme, is required for reactions in different metabolic pathways. To carry out its catalytic action, the carbonyl group present in PLP forms a Schiff’s base with the α-amine of lysine of the apo-enzyme and then the initial catalytic step proceeds by the formation of a Schiff’s base between the α-amine group of an amino-acid and the carbonyl group of PLP. The electron sink properties of PN enable the holo-enzyme for its catalytic reaction. In reactions associated with amino acid metabolism, PLP binding enables the amino acid for further reactions. Some of the reactions PLP is involved in are: transamination of amino acids to keto acids (which can be then used for gluconeogenesis), formation of α-aminolevulic acid (a precursor of heme group), as coenzyme in serin-palmitoyl-transferase (implicated in sphingomyelin synthesis), decarboxylation of L-amino acids (to yield amines, which function as neurotransmitters, hormones or biogenic amines). In the nervous system, PN-dependent enzymes fall into two categories: transaminases and L-amino acid decarboxylases. The crucial PLP-dependent steps of the synthesis of several neurotransmitters are: the enzymatic decarboxylation of 3,4-dihydroxyphenylalanine (DOPA) to dopamine, the conversion of tryptophan to both nitric acid and serotonin, and the conversion of glutamic acid to α-aminobutyric-acid (GABA).

The interaction with the homocysteine (Hcy) metabolism through methionine transformation into cysteine (by cystathionine β-synthase and cystathionine-γ-lyase) is of growing interest since high levels of Hcy have been related to cardiovascular disease (CVD), cognitive impairment or cancer. Hcy is a sulphur-containing amino acid which is not a constituent of proteins and, in fact, an intermediate compound in methionine metabolism. There are two pathways for Hcy disposal in the human body and both are related to methionine status and vitamin B6.

In cases of methionine excess, or when cysteine is required, Hcy enters the transsulfuration pathway which consists of condensation of Hcy with serine to form cystathionine (catalysed by cystathionine-β-synthase). Cystathionine is then degraded to cysteine and α-ketobutyrate by cystathionine γ-lyase. Both reactions require PLP as cofactor. In cases of methionine deficiency, Hcy enters the remethylation pathway which is a folate and B6 dependent process.

As a coenzyme for glycogen phosphorylase, PLP is also involved in glucose metabolism. In this case, the 5-phosphate group of PLP acts as a proton donor or acceptor. In addition to these functions, PLP
interacts with different proteins and plays many different roles including regulation of steroid hormone receptors, modulation of the affinity of haemoglobin into oxygen or inhibition of some transcription factors.

Measurement of vitamin $B_6$

Over the last decades several indicators of $B_6$ status have been developed. Indicators of vitamin $B_6$ status include direct measures, plasma or erythrocyte vitamin concentration, or urinary 4-PA; and functional measures, stimulation or activation of erythrocyte aspartate aminotransferase ($\alpha$-EAST) and alanine aminotransferase ($\alpha$-EALT) by PLP, or determination of tryptophan metabolites, such as urinary xanthurenic acid (XA). The increase in methionine metabolites (e.g. Hcy, cystathionine) after a methionine load is also used as an indicator of $B_6$ status. All of these and their respective reference values are summarised in table I and briefly summed up below.

1. Direct measures in blood and urine.
   (A) Plasma PLP, other vitamers and total vitamin $B_6$

   The PLP concentration is a direct indicator for the activity of vitamin $B_6$ in the organism. Plasma

   and alanine aminotransferase (\(\alpha\text{-EALT}\)) by PLP, or determination of tryptophan metabolites, such as urinary xanthurenic acid (XA). The increase in methionine metabolites (e.g. Hcy, cystathionine) after a methionine load is also used as an indicator of $B_6$ status. All of these and their respective reference values are summarised in table I and briefly summed up below.

1. Direct measures in blood and urine.
   (A) Plasma PLP, other vitamers and total vitamin $B_6$

   The PLP concentration is a direct indicator for the activity of vitamin $B_6$ in the organism. Plasma

   and alanine aminotransferase (\(\alpha\text{-EALT}\)) by PLP, or determination of tryptophan metabolites, such as urinary xanthurenic acid (XA). The increase in methionine metabolites (e.g. Hcy, cystathionine) after a methionine load is also used as an indicator of $B_6$ status. All of these and their respective reference values are summarised in table I and briefly summed up below.

1. Direct measures in blood and urine.
   (A) Plasma PLP, other vitamers and total vitamin $B_6$

   The PLP concentration is a direct indicator for the activity of vitamin $B_6$ in the organism. Plasma

   and alanine aminotransferase (\(\alpha\text{-EALT}\)) by PLP, or determination of tryptophan metabolites, such as urinary xanthurenic acid (XA). The increase in methionine metabolites (e.g. Hcy, cystathionine) after a methionine load is also used as an indicator of $B_6$ status. All of these and their respective reference values are summarised in table I and briefly summed up below.

1. Direct measures in blood and urine.
   (A) Plasma PLP, other vitamers and total vitamin $B_6$

   The PLP concentration is a direct indicator for the activity of vitamin $B_6$ in the organism. Plasma

   and alanine aminotransferase (\(\alpha\text{-EALT}\)) by PLP, or determination of tryptophan metabolites, such as urinary xanthurenic acid (XA). The increase in methionine metabolites (e.g. Hcy, cystathionine) after a methionine load is also used as an indicator of $B_6$ status. All of these and their respective reference values are summarised in table I and briefly summed up below.

1. Direct measures in blood and urine.
   (A) Plasma PLP, other vitamers and total vitamin $B_6$

   The PLP concentration is a direct indicator for the activity of vitamin $B_6$ in the organism. Plasma

   and alanine aminotransferase (\(\alpha\text{-EALT}\)) by PLP, or determination of tryptophan metabolites, such as urinary xanthurenic acid (XA). The increase in methionine metabolites (e.g. Hcy, cystathionine) after a methionine load is also used as an indicator of $B_6$ status. All of these and their respective reference values are summarised in table I and briefly summed up below.

1. Direct measures in blood and urine.
   (A) Plasma PLP, other vitamers and total vitamin $B_6$

   The PLP concentration is a direct indicator for the activity of vitamin $B_6$ in the organism. Plasma

   and alanine aminotransferase (\(\alpha\text{-EALT}\)) by PLP, or determination of tryptophan metabolites, such as urinary xanthurenic acid (XA). The increase in methionine metabolites (e.g. Hcy, cystathionine) after a methionine load is also used as an indicator of $B_6$ status. All of these and their respective reference values are summarised in table I and briefly summed up below.

1. Direct measures in blood and urine.
   (A) Plasma PLP, other vitamers and total vitamin $B_6$

   The PLP concentration is a direct indicator for the activity of vitamin $B_6$ in the organism. Plasma

   and alanine aminotransferase (\(\alpha\text{-EALT}\)) by PLP, or determination of tryptophan metabolites, such as urinary xanthurenic acid (XA). The increase in methionine metabolites (e.g. Hcy, cystathionine) after a methionine load is also used as an indicator of $B_6$ status. All of these and their respective reference values are summarised in table I and briefly summed up below.

1. Direct measures in blood and urine.
   (A) Plasma PLP, other vitamers and total vitamin $B_6$

   The PLP concentration is a direct indicator for the activity of vitamin $B_6$ in the organism. Plasma

   and alanine aminotransferase (\(\alpha\text{-EALT}\)) by PLP, or determination of tryptophan metabolites, such as urinary xanthurenic acid (XA). The increase in methionine metabolites (e.g. Hcy, cystathionine) after a methionine load is also used as an indicator of $B_6$ status. All of these and their respective reference values are summarised in table I and briefly summed up below.

1. Direct measures in blood and urine.
   (A) Plasma PLP, other vitamers and total vitamin $B_6$

   The PLP concentration is a direct indicator for the activity of vitamin $B_6$ in the organism. Plasma

   and alanine aminotransferase (\(\alpha\text{-EALT}\)) by PLP, or determination of tryptophan metabolites, such as urinary xanthurenic acid (XA). The increase in methionine metabolites (e.g. Hcy, cystathionine) after a methionine load is also used as an indicator of $B_6$ status. All of these and their respective reference values are summarised in table I and briefly summed up below.

1. Direct measures in blood and urine.
   (A) Plasma PLP, other vitamers and total vitamin $B_6$

   The PLP concentration is a direct indicator for the activity of vitamin $B_6$ in the organism. Plasma

   and alanine aminotransferase (\(\alpha\text{-EALT}\)) by PLP, or determination of tryptophan metabolites, such as urinary xanthurenic acid (XA). The increase in methionine metabolites (e.g. Hcy, cystathionine) after a methionine load is also used as an indicator of $B_6$ status. All of these and their respective reference values are summarised in table I and briefly summed up below.

1. Direct measures in blood and urine.
   (A) Plasma PLP, other vitamers and total vitamin $B_6$

   The PLP concentration is a direct indicator for the activity of vitamin $B_6$ in the organism. Plasma

   and alanine aminotransferase (\(\alpha\text{-EALT}\)) by PLP, or determination of tryptophan metabolites, such as urinary xanthurenic acid (XA). The increase in methionine metabolites (e.g. Hcy, cystathionine) after a methionine load is also used as an indicator of $B_6$ status. All of these and their respective reference values are summarised in table I and briefly summed up below.
PLP is used as the primary index of whole-body PL levels. Protein bound PLP in the plasma is in equilibrium with free PLP. Binding of PLP to protein protects it from hydrolyses by alkaline phosphatase. The plasma PLP concentration reflects liver PLP15, and changes fairly slowly in response to changes in vitamin intake, taking about 10 days to reach a new steady state. PLP generally correlates with other indicators of B6 status16. Leklem has suggested a plasma PLP concentration of 30 nmol/L as the lower end of normal status17, whereas other investigators have proposed a cut-off of 20 nmol/L. Generally, values lower than 20 nmol/L indicate B6 deficiency. Table II shows different physiological and other parameters which influence PLP plasma concentration14,18. Usually, men show higher levels than women, because of their higher muscle tissue mass. During gestation lower values of this vitamin have been observed, because of heme dilution due to changes in plasma volume. A release of muscle glycogen phosphorylase in prolonged fasting may mask an underlying deficiency, because most PLP in the body is usually bound to this enzyme. Plasma total vitamin B6 and plasma PL concentration are additional direct measures that have utility. Since PL is the form that enters the cell, its measurement may be more relevant than that of PLP.

A number of methods have been developed for the assay of B6 vitamers in plasma for clinical and nutritional purposes. These include microbiological or enzymatic methods. Currently, the quantitative determination of PLP in plasma is commonly performed with procedures that utilise tyrosine apodecarboxylase. Another extensively used method is a chromatographic determination. High-performance liquid chromatography (HPLC) procedures with appropriate detection systems are regarded as the most convenient method for the evaluation of vitamin B6 nutritional status since it is possible to quantify all vitamers and 4-PA in one assay.

(B) 24-hour urinary excretion of 4-PA and total vitamin B6

4-PA is the major inactive metabolite of PN metabolism. Urinary 4-PA has been used extensively to evaluate B6 requirements. Approximately 50% of the B6 intake is excreted as 4-PA, but this proportion can vary somewhat. 4-PA excretion responds almost immediately to changes in dietary intake and therefore reflects recent dietary B6 intake rather than tissue saturation status. Thus, 4-PA excretion should not be used for status assessment. Nevertheless, low urinary excretion implies a low intake. Leklem has suggested a value greater than 3 μmol/day as indicative of adequate status17. Urine levels of 4-PA are lower in females than in males and will be reduced in persons with riboflavin deficiency. Further, different pharmaceuticals (isoniacid, penicillin, and cyclosporine) increase urinary excretion and interfere with the results. Neither age nor alcohol intake affects the measured level.

2. Indirect functional measures

Activation coefficient (AC) of α-EAST and α-EALT

The stimulation of these enzymes by external (added) PLP is a frequently used functional measure of vitamin B6 status. These indicators are considered long-term measures because of the length of the erythrocyte’s lifespan (120 days). Because there is no protein synthesis in mature erythrocytes, the holo-enzyme: apo-enzyme ratio will reflect the availability of PLP at the time the erythrocytes were released into the circulation. In vitamin B6 deficiency, a greater than normal proportion of aminotransferases is present in form of the catalytically inactive apo-enzyme. This can be converted to the catalytically active holo-enzyme by incubation in vitro with PLP. Since the seventies, some authors suggest that α-EALT is a more sensitive index of vitamin B6 nutritional status than is α-EAST19-21. In order to overcome some of the diffe-

| Parameter by which PLP concentration is influenced (modified after Leklem, 1994) |
|------------------|------------------|
| **Parameter** | **Plasma-PLP** |
| Nutrition | ↑ vitamin B6, ↑ protein, ↑ glucose, ↓ bioavailability |
| Physiology | ↑ physical activity, aerobic, ↑ age, ↑ pregnancy, ↑ activity of alkaline phosphatase, ↓ Smoking, ↓ Hypophosphatasia |

Vitamin B6 status, deficiency and its consequences - an overview

Nutr Hosp. 2007;22(1):7-24
rences in methods of measurement and in erythrocyte transaminases activities between normal healthy individuals, the results are generally expressed as an AC (ratio of activity with added coenzyme/activity without added coenzyme). Although complete saturation of aminotransferases with PLP (AC = 1.0) does occur, some degree of unsaturation (AC > 1.0) is considered to be normal. Assuming that erythrocytes must compete with other tissues for the vitamin, and hence that erythrocyte aminotransferase saturation with PLP reflects the status of other tissues, such incomplete saturation may be a factor in normal metabolic regulation. Indicator of deficiency is an AC of EAST of greater than 1.6 and of EALT of greater than 1.25. As mentioned above, EAST-AC reduction lags behind the onset of the PN deficiency. Thus, a low aminotransferase AC value confirms a subacute to chronic deficiency state. Chronic alcoholism causes these indices to be falsely low, and these indices decrease with age.

3. Metabolites (A)

Tryptophan load test (fig. 3)

One of the earliest markers used to determine B6 deficiency was the urinary excretion of XA, which is normally a minor tryptophan catabolite. The major pathway of tryptophan catabolism proceeds via the PLP-dependent kynureninase reaction. The XA pathway also involves PLP-dependent enzymes, but kynurenine aminotransferase seems to be less sensitive to PLP deficiency. Under conditions of B6 deficiency, this minor pathway is used to a greater extent, leading to the increased excretion of abnormal tryptophan metabolites such as XA, and as the deficiency worsens, 3-Hydroxykynurenine (3-HK) and kynurenine. The tryptophan load test has been widely used as an index of vitamin B6 nutritional status. Various challenge doses have been used in different studies such as 2 or 3 grams, as well as 4 grams. However, as for many of the tests of B6 status, it is not clear what level of excretion represents adverse B6 status under the conditions of the tryptophan challenge dose. A 24-hour urinary excretion of less than 65 μmol xanthurenic acid after a 2 g tryptophan oral dose has been suggested. The use of an oral loading dose of L-tryptophan to detect abnormalities in tryptophan and vitamin B6 status is an underutilised laboratory procedure. If used only to measure B6 status, it may be less indicative than other indices, such as the methionine load test (urinary cystathionine), plasma PLP, urinary vitamin B6, or 4-PA. It may, however, be more indicative than erythrocyte aminotransferases. Marginal B6 or magnesium deficiencies cause significant alterations. This test is influenced by protein intake, exercise, lean body mass, and pregnancy. Hormonal factors and infections enhance tryptophan-to-niacin conversion. Thus, this test is most useful for monitoring an individual’s response to PN supplementation rather than for diagnosing a deficiency.

(B) Methionine load test (fig. 4)

A methionine loading test has also been studied as a possible indicator of vitamin B6 status. Three enzymes of the methionine metabolism, cystathionine β-synthase, cystathionine-γ-lyase and cysteine sulphinic acid decarboxylases, are PLP-dependent. In vitamin B6 deficiency, a test dose of methionine (3 g in an adult) results in abnormal accumulation and excretion of Hcy and the mixed disulphide of Hcy and cysteine, as well as cystathionine and cysteine sulphinic acid, and reduced excretion of taurine. More recently a standardi-

![Fig. 3.—Tryptophan load test. PLP: pyridoxal 5'-phosphate.](image-url)
sed methionine load test has been successfully used\textsuperscript{31}. The general procedure involves the administration of 100 mg of L-methionine per kilogram of body weight. The increase in Hcy concentrations are evaluated in terms of the vitamin B6 status. For several reasons, the methionine load test has been used less often as an index of vitamin B\textsubscript{6} nutritional status than has the tryptophan load test.

Pathophysiological implications related to vitamin B\textsubscript{6} deficiency

Since vitamin B\textsubscript{6} is present in almost all foods, B\textsubscript{6} deficiency due to insufficient dietary supply is rare. Additionally, isolated vitamin B\textsubscript{6} deficiency is uncommon; it usually occurs in combination with deficiencies of other B-complex vitamins. Often PN deficiency is caused by absorption disorders, genetic factors, interactions with drugs or elevated requirements as shown in table III. Because of its wide variety of functions in the body, clinical vitamin B\textsubscript{6} deficiency results in a broad spectrum of impaired features. On the other hand, borderline vitamin B\textsubscript{6} deficiency may represent a subtle, undiagnosed and frequent cause of disease in some population groups. In fact, a reduced B\textsubscript{6} status close to borderline concentrations or even mild deficiency could persist in an individual for months or years without the appearance of any of the diagnostic features or symptoms suggesting clinical deficiency. In this situation, some PLP related functions may be adequately compensated but others may not\textsuperscript{32}. This subclinical deficiency can be attributed to inadequate intake and/or to the effect of ageing on physiological and metabolic processes, which may act in conjunction with many other factors. The most common pathophysiological implications related to vitamin B\textsubscript{6} deficiency are the following:

1. **Hypochromic, microcytic, iron-refractory anemia**

B\textsubscript{6}-deficiency anemia is one form of sideroblastic anemia, characterised by ineffective erythropoiesis with hypochromic, microcytic anemia, splenomegaly, elevated tissue and serum iron, and large numbers of ringed sideroblasts in the bone marrow\textsuperscript{33}. Microcytic anemia reflects decreased haemoglobin synthesis. Vitamin B\textsubscript{6} deficiency or a genetic defect of the enzyme aminolevulinate synthase can therefore lead to an iron refractory, microcytic anemia. In animals, it is well established that a deficiency of vitamin B\textsubscript{6} results in a severe microcytic, hypochromic anemia accompanied by strongly elevated serum iron levels\textsuperscript{34}. In humans, vitamin B\textsubscript{6} deficiency anemia is very rare. Therefore, literature is very scarce. In the seventies, Ofori-Nkan-
sah et al. reported that the prevalence is higher in men than in women. Further, Fishman and colleagues suggest that a treatment with B6 may be effective in correcting the haematological abnormalities of sideroblastic anemia.

2. Immune function

Animal studies in the forties demonstrated that a deficiency of vitamin B6 results in large effects on lymphoid tissues. Thymic atrophy occurs and lymphocyte depletion in lymph nodes and spleen has been found in monkeys, dogs, rats, and chickens. More recently, studies performed in humans confirm that vitamin affects immunocompetence. Low vitamin B6 intake and status have been associated with impaired immune function, especially in the elderly. Decreased lymphocyte and interleukin (IL)-2 production has been observed in B6-deficient individuals. Restoration of adequate vitamin B6 status resulted in normalization of lymphocyte proliferation and IL-2 production. These results suggest that adequate vitamin B6 intake is important for optimal immune system function, at least in older individuals.

Further, experimental deficiency in elderly humans has been shown to reduce total blood lymphocyte numbers and decrease the proliferative response of lymphocytes to mitogenic substances. It has been suggested that the mechanism for the effect of vitamin B6 on immune function relates to the importance of PLP in the synthesis of one carbon compounds and hence DNA and RNA synthe-

<table>
<thead>
<tr>
<th>Conditions that increase risk for PN deficiency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Advanced age</td>
</tr>
<tr>
<td>Medical conditions</td>
</tr>
<tr>
<td>Severe malnutrition</td>
</tr>
<tr>
<td>Hospitalization</td>
</tr>
<tr>
<td>Celiac disease</td>
</tr>
<tr>
<td>Hepatitis and extrahepatic biliary obstruction</td>
</tr>
<tr>
<td>Hepatocellular carcinoma</td>
</tr>
<tr>
<td>Chronic renal failure</td>
</tr>
<tr>
<td>Kidney transplant</td>
</tr>
<tr>
<td>Hyperoxaluria types I and II</td>
</tr>
<tr>
<td>High serum alkaline phosphatase level such as in cirrhosis and tissue injury</td>
</tr>
<tr>
<td>Catabolic state</td>
</tr>
<tr>
<td>Medical procedures</td>
</tr>
<tr>
<td>Hemodialysis</td>
</tr>
<tr>
<td>Peritoneal dialysis</td>
</tr>
<tr>
<td>Phototherapy for yperbilirubinaemia</td>
</tr>
<tr>
<td>Social-behavioral conditions</td>
</tr>
<tr>
<td>Excessive alcohol ingestion (except for pyridoxine-supplemented beer)</td>
</tr>
<tr>
<td>Tobacco smoking</td>
</tr>
<tr>
<td>Severe malnutrition</td>
</tr>
<tr>
<td>Other risk factors</td>
</tr>
<tr>
<td>Poisoning, such as Gyromitra mushroom poisoning</td>
</tr>
<tr>
<td>Perinatal factors, such as pyridoxine-deficient mother</td>
</tr>
<tr>
<td>Inherited conditions, such as pyridoxine dependent neonatal seizures</td>
</tr>
<tr>
<td>Other patient history</td>
</tr>
<tr>
<td>Sideroblastic anemia</td>
</tr>
<tr>
<td>Pregnancy</td>
</tr>
<tr>
<td>Physical exercise</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Drug-interaction</th>
<th>Mechanism of interaction</th>
</tr>
</thead>
<tbody>
<tr>
<td>Isoniazid (hydrazines)</td>
<td>Reacts with PL and PLP</td>
</tr>
<tr>
<td>Cycloserine</td>
<td>Reacts with PLP, forms oxime</td>
</tr>
<tr>
<td>L-3,4-Dihydroxyphenylalanine</td>
<td>Reacts with PLP, forms</td>
</tr>
<tr>
<td>derivative</td>
<td>tetrahydroquinoline derivative</td>
</tr>
<tr>
<td>Penicillamine</td>
<td>Reacts with PLP, forms thiazolidine</td>
</tr>
<tr>
<td>Ethinylestradiol, mestranol</td>
<td>Increased enzyme levels and retention of PLP in tissue</td>
</tr>
<tr>
<td>Ethanol</td>
<td>Increased catabolism of PLP</td>
</tr>
<tr>
<td>Theophylline, caffeine</td>
<td>Inhibition of pyridoxal kinase</td>
</tr>
</tbody>
</table>

Table III: Conditions that increase risk for PN deficiency
Evidence of this has been reported. In addition, dis-
that inflammation directly affects vitamin B6 metab-
tus during inflammation. Further, the study indicates
with rheumatoid arthritis. But as improving vitamin B6
contributes to more severe inflammation in patients
5,10-methylene-THF production. Consequently,
SHMT. This results in a lack of methylene groups for
ici instead of thymidine into DNA. As a consequence,
may be impaired resulting in misincorporation of ura-
cle replication. The two different PLP-dependent
zymes which are implicated in the transsulfuration pathway also generate cysteine, an important
component of glutathione. Glutathione S-transferases
and glutathione peroxidases are detoxifying agents of
several carcinogenic compounds. PLP is also involved
in steroid hormone action; consequently, PLP can be
implicated in some types of steroid related cancer.
Some experimental studies suggest that borderline-de-
cicient B6 status increases sensitivity to steroid hor-
omones, and this may have implications for breast, prosta-
te, and uterine carcinogenesis. Furthermore, one
study found a steroid independent inhibition of in vitro
breast cancer cell growth induced by PL and this
was present in oestrogen-dependent and oestrogen-in-
dependent mammary carcinoma cell lines. Many stu-
dies have shown a relation to special types of cancer.
Thus, a more detailed overview may be helpful.

3.1. Colorectal cancer

Komatsu and coworkers demonstrated that vitamin B6 intake decreased both the incidence and the number of colon tumors in an animal model; it decreased colon cell proliferation and expressions of c-myc and c-fos proteins in a dose-dependent manner. More recently, they also showed that the preventive effect of vitamin B6 against colon tumorigenesis in mice is mediated by a reduction of oxidative stress and nitric oxide production.

In humans, Wei et al. found out that in women plasma concentrations of PLP is inversely associated with risk for colorectal cancer (RR = 0.54 for those in the highest vs lowest quartiles, 95% CI = 0.31 to 0.92). Other researchers found an inverse association of vitamin B6 intake and colon cancer. Nevertheless, epidemiologic evidence is still scarce.

3.2. Pancreatic cancer

In a large nested case-control study (included in the ATBC Cancer Prevention Study cohort) a statistically significant inverse dose-response relationship was found between plasma PLP levels and pancreatic cancer risk: the risk of subjects in the highest vs lowest tertile, 95% CI = 0.31 to 0.92. Interestingly, as much as fifty percent of the study population presented lower than adequate plasma PLP concentrations (< 30 nmol/L). This is the first study that observed an inverse association between plasma PLP concentrations and pancreatic cancer risk. Deficiencies in PLP have been shown to impair pancreatic exocrine function in experimental animals. Plasma and pancreatic amylase, trypsin and chymotrypsin activities were found to be significantly decreased in B6 deficient rats. This situation can theoretically lead to incomplete digestion of food, greater duodenal cholecystokinin release, and stimulation of
development of cancer.
pancreatic enzyme production, hyper trophy, and hyperplasia of exocrine tissue, thereby increasing the susceptibility of the pancreas to carcinogens. In fact, chronic hypercholcystokininemias has been shown to enhance pancreatic carcinogenesis in experimental animals\(^\text{55,56}\). Finally, animals receiving inhibitors of cellular methylation reactions develop acute hemorrhagic pancreatitis as a consequence of autolytic destruction of the pancreas\(^\text{65-67}\) and it is well known that chronic pancreatitis increases the risk of pancreatic cancer.

3.3. Gastric, oral and pharyngeal cancer

Several case-control studies have found that high \(B_6\) intake was associated with a decreased risk of gastric adenocarcinomas\(^\text{68-70}\) and oral or pharyngeal cancer\(^\text{71}\).

3.4. Lung cancer

A nested case-control study within the ATBC Cancer Prevention Study found a significantly lower risk of lung cancer among men who had higher plasma \(B_6\) levels. Men presenting high \(B_6\) plasma concentration had about half the risk of lung cancer compared to men with the lowest vitamin \(B_6\) concentrations (OR = 0.51). This is the first report from a prospectively conducted study to suggest a role for vitamin \(B_6\) in lung cancer\(^\text{72}\).

3.5. Prostate and breast cancer

At present, there are no conclusive data relating vitamin \(B_6\) levels and prostate or breast cancer\(^\text{73,74}\). One prospective, nested case-control study showed associations between the average intake of vitamin \(B_6\) (highest vs lowest quintile) and the risk of breast cancer after adjusting for folate intake\(^\text{78}\). Thus, the authors suggest that folate and vitamin \(B_6\) may have the potential to be chemopreventive against breast cancer.

4. Cognitive function

Early findings supporting the implication of vitamin \(B_6\) status in neurocognitive functions are derived from:

a) animal experiments on \(B_6\) deficiency\(^\text{75,76}\);

b) reported cases of neurological abnormalities associated to clinical vitamin deficiency (peripheral neuropathy, seizures)\(^\text{77}\);

c) familial studies on homozygous defects of genes encoding Hcy metabolism enzymes (such as cystathionine-\(\beta\)-synthase defect) which result in mental retardation, psychiatric disturbances and seizures (homocystinuria)\(^\text{80,81}\).

4.1. Findings in the elderly

There are several studies providing evidence for the importance of vitamin \(B_6\) and brain function in the elderly\(^\text{82-84}\). Significant correlations between vitamin \(B_6\) status and memory were found in the Boston Normative Aging Study. Higher concentrations of serum vitamin \(B_6\) were associated with better performance in two memory tests in men (aged 54-81 years) and this association was independent of plasma Hcy levels\(^\text{86}\). Others found a significantly higher Wechsler memory score in the top 90% of vitamin \(B_6\) intake\(^\text{86}\). Furthermore, Deijen and coworkers reported that supplementation with vitamin \(B_6\) could significantly improve memory in elderly men\(^\text{86}\). Additionally, one researcher showed a statistically significant improvement in most of the cognitive function tests in a group of elderly people, supplemented with multivitamins\(^\text{88}\). Subjects with lower blood levels of one or more nutrients showed lower responses on all cognitive-function tests, but there was no significant correlation between single nutrients and cognitive function test scores. This evidence favours the hypothesis that poor vitamin \(B_6\) status could be, at least in part, responsible for the cognitive decline observed in some elderly persons. Further, several studies and meta-analyses have found inverse associations between objective measures of cognitive function and plasma or serum Hcy concentrations\(^\text{82,86-94}\), but others not\(^\text{95,96}\). The increased risk for cerebrovascular disease could be due to a toxic effect of Hcy on vascular tissue\(^\text{91}\). Regarding dementia, the interaction between \(B_6\) and Hcy is not clearly established. A recent study\(^\text{94}\) showed a prevalence of low \(B_6\) levels in 5.3% (\(B_6 < 30 \text{ nmol/L}\)) of a Canadian long-term care population. 46 of 75 residents had a diagnosed dementia and 41.3% showed elevated Hcy levels (Hcy $> 13.3 \text{ μmol/L}$), but no association with \(B_6\). Nevertheless, low vitamin \(B_6\) status has been associated with Alzheimer’s disease (AD) and vascular dementia. Miller and others have recently reported that low PLP levels were strongly associated with AD, but not with cerebrovascular disease\(^\text{94}\). On the contrary, Faßbender and coworkers reported that compared with patients without cerebrovascular disease, patients with subcortical vessel encephalopathy showed significantly decreased plasma concentrations of vitamin \(B_6\)\(^\text{100}\). In both studies, there was an association between Hcy and AD and microangiopathic vascular dementia, respectively, while there was no correlation between Hcy levels and vitamin \(B_6\). Others found that individuals with hyperhomocysteinemia had a higher risk of developing AD compared with those who had normal Hcy levels (OR = 4.6)\(^\text{101}\). Another study found a strong relationship between periventricular and subcortical white matter lesions and low vitamin \(B_6\) levels in patients with AD\(^\text{102}\).

4.2. Convulsive seizures

Since the fifties and sixties, PN deficiency is known to cause convulsive seizures in humans and experimen-
tal animals. Hence, a number of investigators reported disorders in central nervous system (CNS) activity in adults and infants. The neurological disorders in the infants manifested itself within 6 weeks up to 4 months by convulsive seizures, hyperirritability, and abnormal acuteness of the sense of hearing. Two reviews from the eighties summarised research on causative factors responsible for convulsions during vitamin B\textsubscript{6} deficiency. They propose two hypotheses explaining the onset of convulsive seizures. First, it has been shown that a particular nutritional deficiency leads to the accumulation of a potentially hazardous tryptophan metabolite, 3-HK in the CNS. Kynurenine transaminases and kynureninase catalyse are the main routes of 3-HK catabolism and require PLP. Reductions in PLP metabolism and require PLP. Reductions in BA concentrations are reported to be low in the brains of vitamin B\textsubscript{6} deficient infant animals, and such animals are often seen to convulse. Furthermore, pharmacologic studies indicate that drugs diminishing GABA transmission in the CNS promote convulsions.

4.3. EEG alterations

Abnormal EEG-tracing changes were reported in young adult men during experimentally induced vitamin B\textsubscript{6} deficiency in the sixties. The young men were maintained for 21 days on purified diets that provide daily intakes of 0.06 mg vitamin B\textsubscript{6} and either 30 or 100 g protein. The type of EEG abnormalities observed in the young men generally consisted of a slowing of activity with either increased or decreased wave amplitude, and minimal to marked build-up with hyperventilation, particularly in the frontal and parietal leads. More recently studies show EEG abnormalities can develop in women with short-term vitamin B\textsubscript{6}-depletion (< 2 weeks). Abnormal patterns could be reversed administering 0.5 mg vitamin B\textsubscript{6} /day. EEG changes are probably caused by altered neurotransmitter metabolism in the brain and are thought to occur only in cases of frank vitamin B\textsubscript{6} deficiency. However, before ruling out the possibility of EEG abnormalities occurring at marginal levels of vitamin B\textsubscript{6} intake, research employing quantitative analysis of the EEG spectral data should be conducted. To our knowledge such research is still lacking.

4.4. Neuropathies

In the sixties, peripheral neuropathies have been reported in PN deficiency. Demyelination of peripheral nerves has been observed, which could be caused by a disturbance of sphingomyelin synthesis owing to a lack of PLP as cofactor for serine-palmityl-transferase. Recently, peripheral neuropathy caused by vitamin B\textsubscript{6} deficiency has been reported in patients on chronic peritoneal dialysis. Symptoms included paresthesia, burning and painful dysesthesias, and thermal sensations. Interestingly, Gorson and Ropper found in diabetic patients with distal sensory polyneuropathies as most common laboratory abnormalities low levels of vitamin B\textsubscript{6} or B\textsubscript{12}. They concluded that the frequency of low vitamin levels suggests that vitamin B\textsubscript{6} and B\textsubscript{12} levels should be assessed in future studies of diabetic patients with distal sensory polyneuropathies.

5. CVD and Hcy

Suboptimal vitamin B\textsubscript{6} nutriture was first associated with vascular disease following development of atherosclerosis in monkeys fed a B\textsubscript{6} deficient diet. Later, some researchers reported that estimated dietary intake of vitamin B\textsubscript{6} and folate, and plasma concentrations of PLP and folate, were lower in patients who had myocardial infarction than in controls. They also reported that the frequency of myocardial infarction was negatively correlated with both folate and vitamin B\textsubscript{6} nutriture. Others confirmed the association of Hcy and vitamin B\textsubscript{6}. Results of epidemiologic studies suggest that moderately elevated plasma or serum Hcy levels are prevalent in the general population and are associated with increased risk for CVD, independent of classical cardiovascular risk factors. It is still unknown if this is due to the effect of vitamin B\textsubscript{6} on platelet function, connective tissue, blood pressure, thrombogenesis or, indirectly by causing hyperhomocysteinemia. Further, low circulating vitamin B\textsubscript{6} levels have been associated with elevation of the inflammation marker C-reactive protein independently of plasma Hcy.

How to handle vitamin B\textsubscript{6} deficiency?

Although overt clinical deficiency of vitamin B\textsubscript{6} occurs only rarely, nutrition surveys indicate that vitamin B\textsubscript{6} intakes may be marginal or inadequate in segments of the population. Consequently, the presence of a subclinical deficiency may be fairly widespread. Especially in the elderly there is a high prevalence of deficient or borderline vitamin B\textsubscript{6} status. Herrmann and Knapp found vitamin B\textsubscript{6} deficiency in 23% of 65–75 year old and 40% in > 85 year old persons, respectively. According to the SENECA study, 23.3% of the European elderly are B\textsubscript{6} deficient (PLP < 20 nmol/L). A borderline deficient status, which might persist in an individual for a long time without developing clinical manifestations, could have pathological

Vitamin B\textsubscript{6} status, deficiency and its consequences - an overview
consequences. It may contribute to the development of certain diseases, as already stated above.

**Treatment of B₆ deficiency**

1) Treatment of clinical deficiency

Treatment of vitamin B₆ deficiency implies mega doses of this vitamin via oral. Usually around 50 mg/day are administered depending on the cause of the deficiency; higher doses are given if vitamin B₆ deficiency is related to medication use. Some drugs (table III) such as isoniazid, penicillamine, hydralazine, L-Dopa and cycloserine interfere with PLP reacting with the carbonyl groups. The requirements of vitamin B₆ increase in eclampsia and preeclampsia and haemodialysis. B₆-dependent syndromes, which require pharmacological doses of the vitamin, are seldom. These include cystathionine-β-synthase deficiency, PN dependent anemias (especially sideroblastic anemia), and homocystinuria. Treatment consists of very high pharmacological doses of PN. Supplementation of PN hydrochloride in various medical conditions and their doses are shown in table IV.

2) Preventive treatment of borderline, subclinical deficiency

There are some studies showing that especially in the elderly there is a high prevalence of deficient or borderline vitamin B₆ status. Since a subclinical vitamin B₆ deficiency has been associated to several chronic diseases especially in the elderly, a supplementation in this group seems to be indicated. While vitamin B₆ supplementation is an effective treatment for lowering excessively high Hcy levels in patients with PN-responsive homocystinuria due to cystathionine β-synthase deficiency, its role in the prevention or treatment of mild hyperhomocysteinemia remains unclear. Results of 11 studies that investigated the effect of vitamin B₆ on fasting plasma Hcy concentrations are inconclusive. Seven of the aforementioned studies found no change in fasting Hcy, and one found a significant increase. Some studies found a significant reduction in fasting Hcy after vitamin B₆ supplementation. The first of these studies, carried out in young women who had clinical and biochemical vitamin B₆ deficiency, found a significant lowering of fasting Hcy of 19.7% after 15 days of treatment with 20 mg PN hydrochloride/day. The trial, however, was not blinded or placebo-controlled and had no washout period. The second study, a recent placebo-controlled trial, showed a significant lowering of fasting Hcy of 17% (p < 0.011) in response to extremely large doses (120 mg/day) of vitamin B₆ in healthy subjects. McKinley et al. found that in healthy elderly persons who are folate and riboflavin replete, low-dose vitamin B₆ supplementation (1.6 mg/day) effectively lowers fasting Hcy levels by 7.5% (p < 0.008). Since there is more than one vitamin involved in Hcy metabolism, most intervention trials use a combination supplement containing folic acid, vitamin B₁₂, and vitamin B₆ and therefore it is somewhat difficult to conclude the effect of a single vitamin.

**Prevention of B₆ deficiency**

**Dietary reference intakes (DRI)**

According to data from nationally representative US surveys, the median daily intake of B₆ by men is approximately 2 mg/day and the median intake by women is approximately 1.5 mg/day. German data show

---

### Table IV

**Supplementation of PN hydrochloride in various medical conditions (Frye, 2002)**

<table>
<thead>
<tr>
<th>Medical conditions</th>
<th>Doses</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cirrhosis</td>
<td>50 mg/day</td>
</tr>
<tr>
<td>Hemodialysis</td>
<td>5-50 mg/day</td>
</tr>
<tr>
<td>Peritoneal dialysis</td>
<td>2.5-5 mg/day</td>
</tr>
<tr>
<td>Chronic renal failure</td>
<td>2.5-5 mg/day</td>
</tr>
<tr>
<td>Sideroblastic anemia</td>
<td>50-600 mg/day</td>
</tr>
<tr>
<td>PN-dependent seizures</td>
<td>100 mg/day</td>
</tr>
<tr>
<td>Homocystinuria</td>
<td>100-500 mg/day</td>
</tr>
<tr>
<td>Homocysteinemia</td>
<td>100-500 mg/day</td>
</tr>
<tr>
<td>Gyromitra poisoning</td>
<td>25 mg/kg</td>
</tr>
<tr>
<td>Prophylactic administration should be provided when using:</td>
<td></td>
</tr>
<tr>
<td>isoniazid</td>
<td>30-450 mg/day</td>
</tr>
<tr>
<td>penicillamine</td>
<td>100 mg/day</td>
</tr>
<tr>
<td>Estrogen-induced reduction in tryptophan metabolism may require supplementation</td>
<td>20-25 mg/day</td>
</tr>
</tbody>
</table>
the same pattern[^162]. This indicates that the general population is not at risk for developing clinical vitamin B6 deficiency.

Further, the new DRIs set by different international organisations, are now taking into account new aspects to estimate requirements. They do not only focus on the prevention of clinical deficiency, but try to take into account health effects that certain nutrients might have. Even though there is evidence that vitamin B6 could help to prevent CVD, certain types of cancer, and cognitive impairment, present data are insufficient to set EARs based on these new aspects. DRIs and DACH reference values for vitamin B6 are summarised in table V. The recommended dietary allowance (RDA) for adults is 1.3 mg food vitamin B6/day, which lies in the same range as the DACH-settings for men and women, 1.5 and 1.2 mg, respectively[^163]. Most studies of B6 requirements have focused on adults and have been depletion-repletion studies. Clinical symptoms of vitamin B6 deficiency have only been observed during depletion with very low levels of B6 and have never been seen at intakes of 0.5 mg/day or more, suggesting that an intake of 1 mg/day is sufficient for most adults[^2]. The current RDA (1998) for older adults and elderly people (age > 51) are set higher than for younger adults, based on the results of several repletion-depletion studies. Ribaya-Mercado and coworkers employed a vitamin B6 depletion-repletion protocol in healthy elderly and showed that higher than RDA (1989: men: 2.0 mg/day, women: 1.6 mg/day) intakes were necessary to normalise several parameters of vitamin B6 status including enzyme activity, tryptophan metabolism, and plasma vitamers. In a related series of experiments, the amount of vitamin B6 essential to restore several immunologic indices (lymphocyte number and percentages, mitogenic responses, and IL-2 production) to baseline values was also greater than the current DRI (1998)[^40]. Higher levels of fasting insulin and plasma glucose were also observed during the periods of low vitamin B6 status[^164]. Despite evidence that the requirement for vitamin B6 may be slightly higher in older adults, several surveys have found that over half of individuals over age 60 consume less than the current DRI (1.7 mg/day for men and 1.5 mg/day for women). Several studies have found elderly populations to have plasma PLP concentrations below the cut-off threshold for deficiency[^165]. A high prevalence of marginal vitamin B6 deficiency in the elderly is reflected by their reduced activity of α-EAST and α-EALT, increased excretion of XA, and lowered levels of PLP and plasma total vitamin B6[^166-168]. While 50 to 90% of older adults are reported to have die-

<table>
<thead>
<tr>
<th>DRI</th>
<th>DACH-Referene Values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vitamin B6 (mg/day)</td>
<td></td>
</tr>
<tr>
<td>Age</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Men</td>
</tr>
<tr>
<td>0-6 months</td>
<td>–</td>
</tr>
<tr>
<td>7-12 months</td>
<td>–</td>
</tr>
<tr>
<td>1-3 years</td>
<td>0.4</td>
</tr>
<tr>
<td>4-8 years</td>
<td>0.5</td>
</tr>
<tr>
<td>9-13 years</td>
<td>0.8</td>
</tr>
<tr>
<td>14-18 years</td>
<td>1.1</td>
</tr>
<tr>
<td>15-19 years</td>
<td>1.1</td>
</tr>
<tr>
<td>20-24 years</td>
<td>1.4</td>
</tr>
<tr>
<td>31-50 years</td>
<td>1.4</td>
</tr>
<tr>
<td>51-70 years</td>
<td>1.4</td>
</tr>
<tr>
<td>&gt; 70 years</td>
<td>1.4</td>
</tr>
<tr>
<td>&gt; 65 years</td>
<td>1.4</td>
</tr>
<tr>
<td>Pregnancy</td>
<td>1.6</td>
</tr>
<tr>
<td>Lactation</td>
<td>1.7</td>
</tr>
</tbody>
</table>

[^a]: Estimated average requirement  
[^b]: Recommended dietary allowances  
[^c]: Upper level of safe intake; intake of vitamin B6 as pyridoxine  
[^*]: Adequate Intake  
[^1]: > 19 years; < 19 years: 80 mg/day
tary intakes of vitamin B₆ below 1989 RDA levels, several studies indicate that the physiologic requirement may exceed these recommended values¹⁶⁹,¹⁷⁰. Considering this, it is not understandable why the DACH reference values are not set higher for older adults (> 51 years) or even lower for men of the age 71 and older.

Food fortification

The possibility to enrich food with vitamins allows it to increase the health status of the population. The United States and Canada started with the first official guidelines concerning the fortification of food with folic acid. Further, Hungary and Chile followed the guidelines and voluntary fortification is present in Switzerland, Australia and Great Britain. Due to the interrelationship of the vitamins that participate in the Hcy cycle, it has been debated if vitamin B₆ (and vitamin B₁₂) should be added to folate-enriched foods. From the different countries that enrich their flour with folate, only in Hungary vitamin B₆ is added (880 μg/100 g flour) beside vitamin B₁₂ with 0.8 μg and folic acid with 160 μg¹⁷¹.

Toxicity

Values of maximum tolerable intakes are summarised in table VI. As a water-soluble vitamin which is rapidly metabolised and excreted, B₆ might be expected to have low toxicity. In fact, no adverse effects have been associated with high intake of vitamin B₆ from food sources. Schaumburg and others reported the development of severe sensory neuropathy in 7 patients treated with 2-6 g of PN hydrochloride/day¹⁷². Further, reports of peripheral sensory neuropathy associated with high-dose PN therapy (1 to 4 g/day) appeared also in the 1980s¹⁷³-¹⁷⁶. However, it is noteworthy that none of the reviews of patients with vitamin B₆ dependency syndromes, who are treated with 500-1,500 mg/day, mentions the development of peripheral neuropathy¹⁷⁷. Some patients developed abnormally low plasma concentrations of PLP after high doses of vitamin B₆. This rebound avitaminosis presumably reflects induction of pyridoxal oxidase, and hence increased catabolism of the vitamin. Within 4 months, plasma concentrations of the vitamin return to normal without supplementation¹⁷⁸. The limited data involving lower PN doses reveal that the risk of developing sensory neuropathy decreases rapidly at doses below 1 g/day¹⁷⁹,¹⁸⁰. The safe upper limit for vitamin B₆ has been set at 100 mg/day, taking into account a security factor of 5, because the lowest dose at which toxicity (sensory neuropathy) has been observed is 500 mg/day².

<table>
<thead>
<tr>
<th>Food</th>
<th>Content (mg/100 g)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beef liver</td>
<td>0.90</td>
</tr>
<tr>
<td>Pork</td>
<td>0.39</td>
</tr>
<tr>
<td>Chiken</td>
<td>0.50</td>
</tr>
<tr>
<td>Beef</td>
<td>0.50</td>
</tr>
<tr>
<td>Salmon</td>
<td>0.98</td>
</tr>
<tr>
<td>Tuna</td>
<td>0.46</td>
</tr>
<tr>
<td>Egg</td>
<td>0.12</td>
</tr>
<tr>
<td>Whole milk</td>
<td>0.05</td>
</tr>
<tr>
<td>Cream cheese (20%)</td>
<td>0.09</td>
</tr>
<tr>
<td>Spinach, raw</td>
<td>0.20</td>
</tr>
<tr>
<td>Potatoes, raw</td>
<td>0.21</td>
</tr>
<tr>
<td>Pes, green, raw</td>
<td>0.16</td>
</tr>
<tr>
<td>Broccoli, raw</td>
<td>0.17</td>
</tr>
<tr>
<td>Carrots</td>
<td>0.30</td>
</tr>
<tr>
<td>Apple, unpeeled, raw</td>
<td>0.10</td>
</tr>
<tr>
<td>Banana, raw</td>
<td>0.37</td>
</tr>
<tr>
<td>Grapes, raw</td>
<td>0.13</td>
</tr>
<tr>
<td>Walnuts</td>
<td>0.87</td>
</tr>
<tr>
<td>Wheat germ</td>
<td>4.00</td>
</tr>
<tr>
<td>Wheat flour, whole grain</td>
<td>0.46</td>
</tr>
<tr>
<td>Rye bread</td>
<td>0.20</td>
</tr>
<tr>
<td>Bread, white</td>
<td>0.04</td>
</tr>
<tr>
<td>Rice, white</td>
<td>0.18</td>
</tr>
<tr>
<td>Rice, brown</td>
<td>0.67</td>
</tr>
<tr>
<td>Spaghetti with tomato sauce</td>
<td>0.12</td>
</tr>
<tr>
<td>Pizza, all kinds</td>
<td>0.41</td>
</tr>
<tr>
<td>Pancakes</td>
<td>0.02</td>
</tr>
<tr>
<td>Yeast</td>
<td>0.81</td>
</tr>
<tr>
<td>Human milk</td>
<td>0.01</td>
</tr>
</tbody>
</table>

Acknowledgement

This work was supported by the Spanish Ministry of Health (FIS No PI 021830) and the 6th Frame Programme of the European Community (HELENA-Study; “Healthy Lifestyle in Europe by Nutrition and Adolescence”; EC 007034).

References

Vitamin B6 status, deficiency and its consequences - an overview


Vitamin B6 status, deficiency and its consequences - an overview

A. Spinneker y cols.


